Study of the Effect of Transcranial Stimulations in Aphasic Subject Within a Year of Their Stroke
NCT ID: NCT02101398
Last Updated: 2025-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
5 participants
INTERVENTIONAL
2014-10-02
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TDCS and Aphasia Therapy in the Acute Phase After Stroke
NCT03297450
Using Transcranial Direct Current Stimulation (tDCS) to Improve Post-Stroke Aphasia
NCT01709383
Interest of Combining Speech Therapy With a Non-invasive Brain Stimulation (tDCS) for the Aphasic Patient
NCT02612753
Transcranial Direct Current Stimulation for Post-Stroke Aphasia
NCT02461355
Transcranial Direct Current Stimulation (tDCS) and Intensive Therapy in Aphasia
NCT03510182
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
F7A
Anodal electrode set on the left Broca's area and cathodal electrode set on its right homologue. Active stimulation.
eldith DC-stimulator, configuration F7A
tDCS will be delivered during a 20 minutes speech-language therapy session
F7C
Cathodal electrode set on the left Broca's area and anodal electrode set on its right homologue. Active stimulation.
eldith DC-stimulator, configuration F7C
tDCS will be delivered during a 20 minutes speech-language therapy session
T5A
Anodal electrode set on the left Wernicke's area and cathodal electrode set on its right homologue. Active stimulation.
eldith DC-stimulator, configuration T5A
tDCS will be delivered during a 20 minutes speech-language therapy session
T5C
Cathodal electrode set on the left Wernicke's area and anodal electrode set on its right homologue. Active stimulation.
eldith DC-stimulator, configuration T5C
tDCS will be delivered during a 20 minutes speech-language therapy session
Sham
Electrodes set on the left Broca's area and its right homologue or electrodes set on the left Wernicke's area and its right homologue, but no stimulation will be delivered.
eldith DC-stimulator, configuration Sham
Sham tDCS will be delivered during a 20 minutes speech-language therapy session
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
eldith DC-stimulator, configuration F7A
tDCS will be delivered during a 20 minutes speech-language therapy session
eldith DC-stimulator, configuration F7C
tDCS will be delivered during a 20 minutes speech-language therapy session
eldith DC-stimulator, configuration T5A
tDCS will be delivered during a 20 minutes speech-language therapy session
eldith DC-stimulator, configuration T5C
tDCS will be delivered during a 20 minutes speech-language therapy session
eldith DC-stimulator, configuration Sham
Sham tDCS will be delivered during a 20 minutes speech-language therapy session
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aphasic patient following a first left hemispheric stroke
* BDAE 3.0 aphasia score \> or = to 1
* stroke within 3 to 12 months before inclusion in the study
* mother tongue = French
* right handedness
* signed informed consent
Exclusion Criteria
* epileptic seizure within 2 months before inclusion
* dementia
* bilingual patient (2 mother tongues)
* history of cranial surgery
* presence of intracerebral metallic material
* unauthorized molecules at inclusion : sulpiride, rivastigmine, dextromethorphan, carbamazepine, flunarizine, levodopa
* pregnant, parturient or lactating woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolas ROCHE, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpital Raymond Poincaré
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Raymond Poincaré
Garches, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-A00989-36
Identifier Type: REGISTRY
Identifier Source: secondary_id
C12-09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.